|
1
|
Prasad A, Gersh BJ, Mehran R, Brodie BR,
Brener SJ, Dizon JM, Lansky AJ, Witzenbichler B, Kornowski R,
Guagliumi G, et al: Effect of ischemia duration and door-to-balloon
time on myocardial perfusion in ST-segment elevation myocardial
infarction: An analysis from HORIZONS-AMI trial (harmonizing
outcomes with revascularization and stents in acute myocardial
infarction). JACC Cardiovasc Interv. 8:1966–1974. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Grygier M, Araszkiewicz A, Lesiak M, Janus
M, Kowal J, Skorupski W, Pyda M, Mitkowski P and Grajek S: New
method of intracoronary adenosine injection to prevent
microvascular reperfusion injury in patients with acute myocardial
infarction undergoing percutaneous coronary intervention. Am J
Cardiol. 107:1131–1135. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim
WS, Seon HJ and Kim KS: Cardioprotective effects of exenatide in
patients with ST-segment-elevation myocardial infarction undergoing
primary percutaneous coronary interventio: Results of exenatide
myocardial protection in revascularization study. Arterioscler
Thromb Vasc Biol. 33:2252–2260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hamarneh A, Sivaraman V, Bulluck H,
Shanahan H, Kyle B, Ramlall M, Chung R, Jarvis C, Xenou M, Ariti C,
et al: The effect of remote ischemic conditioning and glyceryl
trinitrate on perioperative myocardial injury in cardiac bypass
surgery patients: Rationale and design of the ERIC-GTN study. Clin
Cardiol. 38:641–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Toldo S, Marchetti C, Mauro AG, Chojnacki
J, Mezzaroma E, Carbone S, Zhang S, Van Tassell B, Salloum FN and
Abbate A: Inhibition of the NLRP3 inflammasome limits the
inflammatory injury following myocardial ischemia-reperfusion in
the mouse. Int J Cardiol. 209:215–220. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu SY, Tang L, Zhao GJ and Zhou SH: Statin
protects the heart against ischemia-reperfusion injury via
inhibition of the NLRP3 inflammasome. Int J Cardiol. 229:23–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle Raleigh J, Mauro AG, Devarakonda T,
Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A and
Salloum FN: Reperfusion therapy with recombinant human relaxin-2
(Serelaxin) attenuates myocardial infarct size and NLRP3
inflammasome following ischemia/reperfusion injury via
eNOS-dependent mechanism. Cardiovasc Res. 113:609–619.
2017.PubMed/NCBI
|
|
8
|
Wu Y, Tan X, Tian J, Liu X, Wang Y, Zhao
H, Yan Z, Liu H and Ma X: PPARγ agonist ameliorates the impaired
fluidity of the myocardial cell membrane and cardiac injury in
hypercholesterolemic rats. Cardiovasc Toxicol. 17:25–34. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ravingerova T, Adameova A, Carnicka S,
Nemcekova M, Kelly T, Matejikova J, Galatou E, Barlaka E and Lazou
A: The role of PPAR in myocardial response to ischemia in normal
and diseased heart. Gen Physiol Biophys. 30:329–341. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rezaee R, Behravan E, Behravan J, Soltani
F, Naderi Y, Emami B and Iranshahi M: Antigenotoxic activities of
the natural dietary coumarins umbelliferone, herniarin and
7-isopentenyloxy coumarin on human lymphocytes exposed to oxidative
stress. Drug Chem Toxicol. 37:144–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chunhua M, Lingdong K, Hongyan L and
Zhangqiang M: Retracted: Umbelliferone reverses depression-like
behavior in chronic unpredictable mild stress-induced mice via
RIP140/NF-κB pathway. IUBMB Life. 69:7672017. View Article : Google Scholar
|
|
12
|
Vijayalakshmi A and Sindhu G: Dose
responsive efficacy of umbelliferone on lipid peroxidation,
anti-oxidant, and xenobiotic metabolism in DMBA-induced oral
carcinogenesis. Biomed Pharmacother. 88:852–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hofsten DE, Kelbaek H, Helqvist S,
Kløvgaard L, Holmvang L, Clemmensen P, Torp-Pedersen C, Tilsted HH,
Bøtker HE, Jensen LO, et al: The third DANish study of optimal
acute treatment of patients with ST-segment elevation myocardial
infarction: Ischemic postconditioning or deferred stent
implantation versus conventional primary angioplasty and complete
revascularization versus treatment of culprit lesion only:
Rationale and design of the DANAMI 3 trial program. Am Heart J.
169:613–621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hausenloy DJ, Candilio L, Laing C, Kunst
G, Pepper J, Kolvekar S, Evans R, Robertson S, Knight R, Ariti C,
et al: Effect of remote ischemic preconditioning on clinical
outcomes in patients undergoing coronary artery bypass graft
surgery (ERICCA): Rationale and study design of a multi-centre
randomized double-blinded controlled clinical trial. Clin Res
Cardiol. 101:339–348. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu YL, Kampinga MA, Wieringa WG, Fokkema
ML, Nijsten MW, Hillege HL, Van den Heuvel AF, Tan ES, Pundziute G,
van der Werf R, et al: Intracoronary versus intravenous
administration of abciximab in patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous coronary
intervention with thrombus aspiration: The comparison of
intracoronary versus intravenous abciximab administration during
emergency reperfusion of ST-segment elevation myocardial infarction
(CICERO) trial. Circulation. 122:2709–2717. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pei H, Song X, Peng C, Tan Y, Li Y, Li X,
Ma S, Wang Q, Huang R, Yang D, et al: TNF-α inhibitor protects
against myocardial ischemia/reperfusion injury via Notch1-mediated
suppression of oxidative/nitrative stress. Free Radic Biol Med.
82:114–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yue R, Xia X, Jiang J, Yang D, Han Y, Chen
X, Cai Y, Li L, Wang WE and Zeng C: Mitochondrial DNA oxidative
damage contributes to cardiomyocyte ischemia/reperfusion-injury in
rats: Cardioprotective role of lycopene. J Cell Physiol.
230:2128–2141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu Z, Wang S, Zhang X, Li Y, Zhao Q and
Liu T: Pterostilbene protects against myocardial
ischemia/reperfusion injury via suppressing oxidative/nitrative
stress and inflammatory response. Int Immunopharmacol. 43:7–15.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng P, Xie Z, Yuan Y, Sui W, Wang C, Gao
X, Zhao Y, Zhang F, Gu Y, Hu P, et al: Plin5 alleviates myocardial
ischaemia/reperfusion injury by reducing oxidative stress through
inhibiting the lipolysis of lipid droplets. Sci Rep. 7:425742017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Zhang J, Yu P, Chen M, Peng Q,
Wang Z and Dong N: Remote ischaemic preconditioning and sevoflurane
postconditioning synergistically protect rats from myocardial
injury induced by ischemia and reperfusion partly via Inhibition
TLR4/MyD88/NF-κB signaling pathway. Cell Physiol Biochem. 41:22–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sandanger Ø, Ranheim T, Vinge LE, Bliksøen
M, Valen G, Aukrust P and Yndestad A: A role for NLRP3 inflammasome
in acute myocardial ischaemia-reperfusion injury? Reply. Cardiovasc
Res. 99:226–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sandanger Ø, Ranheim T, Vinge LE, Bliksøen
M, Alfsnes K, Finsen AV, Dahl CP, Askevold ET, Florholmen G,
Christensen G, et al: The NLRP3 inflammasome is up-regulated in
cardiac fibroblasts and mediates myocardial ischaemia-reperfusion
injury. Cardiovasc Res. 99:164–174. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X, Li R, Wang X, Fu Q and Ma S:
Umbelliferone ameliorates cerebral ischemia-reperfusion injury via
upregulating the PPAR gamma expression and suppressing TXNIP/NLRP3
inflammasome. Neurosci Lett. 600:182–187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Yu Z, Huang X, Gao Y, Wang X, Gu J
and Xue S: Peroxisome proliferator-activated receptor γ (PPARγ)
mediates the protective effect of quercetin against myocardial
ischemia-reperfusion injury via suppressing the NF-κB pathway. Am J
Transl Res. 8:5169–5186. 2016.PubMed/NCBI
|
|
25
|
Qian J, Chen H, Birnbaum Y, Nanhwan MK,
Bajaj M and Ye Y: Aleglitazar, a balanced dual PPARα and -γ
agonist, protects the heart against ischemia-reperfusion injury.
Cardiovasc Drugs Ther. 30:129–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mahmoud AM, Germoush MO, Alotaibi MF and
Hussein OE: Possible involvement of Nrf2 and PPARγ up-regulation in
the protective effect of umbelliferone against
cyclophosphamide-induced hepatotoxicity. Biomed Pharmacother.
86:297–306. 2017. View Article : Google Scholar : PubMed/NCBI
|
